Is Further Evaluation of Areas with Faint MDP Uptake Needed in Individuals with Oligo-Metastatic Prostatic Adenocarcinoma?

Abstract

A 42-year-old male patient with high-risk prostate adenocarcinoma underwent baseline ^99mTc-methylene diphosphonate skeletal scintigraphy, which revealed two skeletal metastases and an area of faint radiotracer uptake in the left femoral shaft. In view of oligo-metastatic nature of the disease in the bone scan and the young age of the patient, he was a candidate for metastases-directed treatment. Single photon emission computed tomography (SPECT)/CT was performed to further characterize this lesion. It was revealed to be a small soft tissue density lesion within the fatty bone marrow density, suggesting bone marrow involvement. A more sensitive evaluation of such areas with faint radiotracer uptake may be needed in high-risk prostate cancer patients where access to advanced modalities is limited. Their significance will also need reassessment as their detection will improve with technological advancements.

Keywords

high-risk prostate cancer - ^99mTc-MDP - skeletal scintigraphy - bone marrow metastasis - oligometastatic disease

Informed Consent

Permission was taken from the patient before submitting this case study.

Publikationsverlauf

Artikel online veröffentlicht:
28. Oktober 2022

• References

• 1 Rawla P. Epidemiology of prostate cancer. World J Oncol 2019; 10 (02) 63-89
• 2 Cancer of the Prostate - Cancer Stat Facts [Internet]. SEER. [cited 2022 Feb]. Assessed August 18, 2022, at: https://seer.cancer.gov/statfacts/html/prost.html
• 3 Broughman JR, Fleming CW, Mian OY, Stephans KL, Tendulkar RD. Management of oligometastatic prostate cancer. Appl Radiat Oncol 2020; 9 (03) 6-10
• 4 Tosoian JJ, Gorin MA, Ross AE, Pienta KJ, Tran PT, Schaeffer EM. Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations. Nat Rev Urol 2017; 14 (01) 15-25
• 5 Professionals S-O. EAU Guidelines: Prostate Cancer [Internet]. Uroweb. [cited 2022 Feb]. Assessed August 18, 2022, at: https://uroweb.org/guideline/prostate-cancer/
• 6 Raju S, Sharma A, Patel C. et al. Is there a utility of adding skeletal imaging to 68-Ga-prostate-specific membrane antigen-PET/computed tomography in initial staging of patients with high-risk prostate cancer?. Nucl Med Commun 2020; 41 (11) 1183-1188
• 7 Corfield J, Perera M, Bolton D, Lawrentschuk N. ⁶⁸Ga-prostate specific membrane antigen (PSMA) positron emission tomography (PET) for primary staging of high-risk prostate cancer: a systematic review. World J Urol 2018; 36 (04) 519-527
• 8 Lengana T, Lawal IO, Boshomane TG. et al. ⁶⁸Ga-PSMA PET/CT replacing bone scan in the initial staging of skeletal metastasis in prostate cancer: a fait accompli?. Clin Genitourin Cancer 2018; 16 (05) 392-401
• 9 Sharma A, Pandey AK, Khichi D, Kumar R. Methylene diphosphonate bone scan scintigraphic image enhancement using gamma correction and optimizing the value of gamma. Indian J Nucl Med 2020; 35 (01) 21-27